B
Bull
Bull · 25%KMDA
$7.88
Scenario price
$7.770
+0.040 (+0.52%)At close
Loading chart…
- High
- 7.800
- Open
- 7.710
- VWAP
- 7.75
- Volume
- 88.20K
- Mkt Cap
- 289.98M
- Low
- 7.680
- Amount
- 683.57K
- EV/EBITDA, TTM
- 3.20
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
AI analysis of Kamada Ltd (KMDA)
BuyKamada Ltd appears to be a good buy right now due to its recent FDA approval for a new laboratory, which enhances its operational capabilities and positions it well in the growing rabies immunoglobulin market. The current price of $7.77 is below the Fibonacci R1 level of $7.94, suggesting potential upside. Additionally, the company has shown a strong gross margin of 40.91% in Q2 2026, indicating solid profitability. However, a key risk is the recent Q1 earnings miss, where EPS was $0.07, falling short of expectations by $0.05, which could impact investor sentiment in the short term.
Analyst Ratings (1)
+80.18% upside
Buy
1 Buy
0 Hold
0 Sell
Current: 7.77
Low
13.00
Average
14.00
High
15.00
H.C. Wainwright
Buy
$13
2025-12-09
H.C. Wainwright
2025-12-09
Price Target
$13
Buy
Benchmark
Strong Buy
$15
2025-03-21
Benchmark
2025-03-21
Price Target
$15
Strong Buy
HC Wainwright & Co.
Strong Buy
$11
2025-03-06
HC Wainwright & Co.
2025-03-06
Price Target
$11
Strong Buy
HC Wainwright & Co.
Strong Buy
$11
2025-01-10
HC Wainwright & Co.
2025-01-10
Price Target
$11
Strong Buy
HC Wainwright & Co.
Strong Buy
$11
2024-11-14
HC Wainwright & Co.
2024-11-14
Price Target
$11
Strong Buy
Valuation Metrics
The current forward P/E ratio for Kamada Ltd (KMDA) is 16.53, compared to its 5-year average forward P/E of 6.62.
Alphio AI Price Scenarios for KMDA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding KMDA
Events Timeline
News
1.010-19NewsfilterKamada CEO to Attend Investor Conferences in November
7.509-17NASDAQ.COMKamada Addresses Surge in U.S. Rabies Demand
- 8.008-17Newsfilter
Kamada Declares $0.17 Cash Dividend Per Share
- 5.008-12Newsfilter
Kamada CFO Chaime Orlev to Depart for New Opportunities
- 9.508-12Newsfilter
Kamada Reports Record $100.2 Million Revenue in First Half of 2026
KMDA FAQ — answered by Alphio AI
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Kamada Ltd appears to be a good buy right now due to its recent FDA approval for a new laboratory, which enhances its operational capabilities and positions it well in the growing rabies immunoglobulin market. The current price of $7.77 is below the Fibonacci R1 level of $7.94, suggesting potential upside. Additionally, the company has shown a strong gross margin of 40.91% in Q2 2026, indicating solid profitability. However, a key risk is the recent Q1 earnings miss, where EPS was $0.07, falling short of expectations by $0.05, which could impact investor sentiment in the short term.
1 analysts cover KMDA: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.00.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.